mbiomics
Germany, Neuried, Bavaria
About mbiomics
mbiomics is a Munich-based techbio company developing live biotherapeutic products (LBPs) — orally administered, pharmaceutical-grade complex microbial consortia — for severe and chronic diseases. Its proprietary platform combines AI/ML-driven consortia design, high-resolution microbiome profiling, and large-scale co-cultivation to make microbiome therapeutics scalable. The company's lead candidate MBX-116 is being advanced toward a Phase 1B clinical trial in 2027 as a co-therapy with immune checkpoint inhibitors in advanced melanoma, with a broader pipeline targeting autoimmune and neurodegenerative indications.
Latest Funding
Series AAnnounced 2026-04-28
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
5 signals · where the capital is going
Accelerate GMP development and scalable manufacturing of complex microbial consortia / live biotherapeutic products.
globenewswire.com
Advance lead candidate MBX-116 toward clinical evaluation as an immune checkpoint inhibitor co-therapy in advanced melanoma, targeting a Phase 1B start in 2027.
globenewswire.com
+3 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to mbiomics? You're in the right place.
Knowing they raised is the start. The edge is what's attached to mbiomics.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of mbiomics, and who are their main competitors?
Sign up free to ask AI about mbiomics
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Bayern Kapital
Lead investor · Series A
Tech Stack
React
HSTS
HTTP/3
Contacts
Sarah M.
Head of Sales
Sample preview. Sign up free to see real contacts
Key Highlights
AI InsightsThird closing added €12 million on top of two prior tranches, bringing the total Series A round size to €30 million since the first closing in March 2023.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to mbiomics
Selling to mbiomics? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to mbiomics.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.